Table 2.

IL-12 Abrogates Generation of Antigen-Specific IFN-γ Responses to Recombinant Vaccinia Vaccines in C57BL/6 Mice^a

In vivo vaccination:	rVV-hgp100		rVV-hgp100 + IL-12		rVV-βgal		rVV-βgal + IL-12
In vitro restimulation:	hgp100 pep	βgal pep	hgp100 pep	βgal pep	hgp100 pep	βgal pep	hgp100 pep	βgal pep
Experiment 1
Test antigen
None	67	100	565	226	118	62	52	1,365
hgp100 pep	19,963	42	588	341	49	93	68	471
βgal pep	71	250	545	386	68	13,525	40	821
Experiment 2
Test antigen
None	288	380	111	130	416	180	150	827
hgp100 pep	38,429	476	130	66	3,237	693	102	190
βgal pep	1,268	1,009	244	150	2,084	20,275	288	404

^aC57BL/6 mice were vaccinated with recombinant vaccinia virus expressing either the human gp100 or βgal protein on day 0. Either PBS or 1 µg rMuIL-12 was administered i.p. on days 0–4. On day 21, splenocytes were restimulated in vitro with either hgp100 or βgal peptide and tested 6 days later with the indicated peptide for antigen-specific IFN-γ release.